Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer

Pharmaceutical Research

Volumn 29, Issue 11, 2012, Pages 3053-3063

  Li, Chien Ming ^a   Lu, Yan ^b   Chen, Jianjun ^b   Costello, Terrence A ^a   Narayanan, Ramesh ^a   Dalton, Mara N ^a   Snyder, Linda M ^a   Ahn, Sunjoo ^a   Li, Wei ^b   Miller, Duane D ^b   Dalton, James T ^a,c  

^a GTx Inc   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c NONE   (United States)

Author keywords

P glycoprotein; paclitaxel resistant cancer; pharmacokinetics; tubulin; xenograft

Indexed keywords

AGENTS AFFECTING CELL DIVISION; ANTINEOPLASTIC AGENT; COLCHICINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOCETAXEL; FURAFYLLINE; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PODOPHYLLOTOXIN; QUINIDINE; SULFAPHENAZOLE; TICLOPIDINE; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE; [2 (1H INDOL 3 YL) 1H IMIDAZOL 4 YL] (3,4,5 TRIMETHOXYPHENYL)METHANONE; [2 (1H INDOL 5 YLAMINO)THIAZOL 4 YL] (3,4,5 TRIMETHOXYPHENYL)METHANONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOG; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STABILITY; ENZYME INHIBITION; ENZYME SPECIFICITY; FEMALE; GLIOMA; IC 50; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN POLYMERIZATION; RAT; SINGLE DRUG DOSE; SOLID TUMOR; TUMOR XENOGRAFT;

EID: 84867847194     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0814-5     Document Type: Article

References (33)

1. Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998;18(4):259-96.
2. Desai A, Mitchison TJ. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol. 1997;13:83-117.
3. Jordan, M. A.; Wilson, L. In The Role of Microtubules in Cell Biology, Neurobiology, and Oncology; Fojo, T., Ed.; Humana Press: Totowa, 2008; pp 47-81.
4. Jordan MA, Kamath K. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets. 2007;7(8):730-42.
5. Denduluri N, Swain S. Ixabepilone: clinical role in metastatic breast cancer. Clin Breast Cancer. 2011;11(3):139-45.
6. Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor EL. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590-8.
7. Koolen SL, Beijnen JH, Schellens JH. Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. Clin Pharmacol Ther. 2010;87(1):126-9.
8. Malingre MM, Beijnen JH, Schellens JH. Oral delivery of taxanes. Invest New Drugs. 2001;19(2):155-62.
9. Malingre MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. Cancer Chemother Pharmacol. 2001;47(4):347-54.
10. Cheng KL, Bradley T, Budman DR. Novel microtubule-targeting agents - the epothilones. Biologics. 2008;2(4):789-811.
11. Fox E, Maris JM, Cohn SL, Goodspeed W, Goodwin A, Kromplewski M, et al. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol. 2010;66(4):737-43.
12. Michels J, Ellard SL, Le L, Kollmannsberger C, Murray N, Tomlinson Guns ES, et al. A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Ann Oncol. 2010;21(2):305-11.
13. Mauer AM, Cohen EE, Ma PC, Kozloff MF, Schwartzberg L, Coates AI, et al. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2008;3(6):631-6.
14. Oostendorp RL, Witteveen PO, Schwartz B, Vainchtein LD, Schot M, Nol A, et al. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. Invest New Drugs. 2010;28(2):163-70.
15. Bacher G, Nickel B, Emig P, Vanhoefer U, Seeber S, Shandra A, et al. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res. 2001;61(1):392-9.
16. Foster PA, Stengel C, Ali T, Leese MP, Potter BV, Reed MJ, et al. A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. Anticancer Res. 2008;28(3A):1483-91.
17. Day JM, Foster PA, Tutill HJ, Newman SP, Ho YT, Leese MP, et al. BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure. Br J Cancer. 2009;100(3):476-86.
18. Marrelli M, Conforti F, Statti GA, Cachet X, Michel S, Tillequin F, et al. Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4. Curr Med Chem. 2011;18(20):3035-81.
19. Chaplin DJ, Hill SA. The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys. 2002;54(5):1491-6.
20. Ng QS, Mandeville H, Goh V, Alonzi R, Milner J, Carnell D, et al. Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol. 2012;23(1):231-7.
21. Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol. 2011;22(9):2036-41.
22. Lu Y, Li CM, Wang Z, Chen J, Mohler ML, Li W, et al. Design, Synthesis, and SAR Studies of 4-Substituted Methoxylbenzoyl-aryl-thiazoles Analogues as Potent and Orally Bioavailable Anticancer Agents. J Med Chem. 2011;54(13):4678-93.
23. Li CM, Chen J, Lu Y, Narayanan R, Parke DN, Li W, et al. Pharmacokinetic Optimization of 4-Substituted Methoxybenzoyl-Aryl-Thiazole (SMART) and 2-Aryl-4-Benzoyl-Imidazole (ABI) for Improving Oral Bioavailability. Drug Metab Dispos. 2011;30(10):1833-9.
24. Chen J, Wang Z, Li CM, Lu Y, Vaddady PK, Meibohm B, et al. Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. J Med Chem. 2010;53(20):7414-27.
25. Chen J, Li CM, Wang J, Ahn S, Wang Z, Lu Y, et al. Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization. Bioorg Med Chem. 2011;19(16):4782-95.
26. Ogunbiyi OJ. Impact of health system challenges on prostate cancer control: health care experiences in Nigeria. Infect Agent Cancer. 2011;6 Suppl 2:S5.
27. Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET, et al. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate. 2007;67(9):955-67.
28. Li CM, Wang Z, Lu Y, Ahn S, Narayanan R, Kearbey JD, et al. Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitor. Cancer Res. 2011;71(1):216-24.
29. Li CM, Lu Y, Ahn S, Narayanan R, Miller DD, Dalton JT. Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin. J Mass Spectrom. 2010;45(10):1160-6.
30. Behrens I, Kissel T. Do cell culture conditions influence the carrier-mediated transport of peptides in Caco-2 cell monolayers? Eur J Pharm Sci. 2003;19(5):433-42.
31. Natoli M, Leoni BD, D'Agnano I, D'Onofrio M, Brandi R, Arisi I, et al. Cell growing density affects the structural and functional properties of Caco-2 differentiated monolayer. J Cell Physiol. 2011;226(6):1531-43.
32. Nguyen L, Zhong WZ, Painter CL, Zhang C, Rahavendran SV, Shen Z. Quantitative analysis of PD 0332991 in xenograft mouse tumor tissue by a 96-well supported liquid extraction format and liquid chromatography/mass spectrometry. J Pharm Biomed Anal. 2010;53(3):228-34.
33. Ahn S, Duke 3rd CB, Barrett CM, Hwang DJ, Li CM, Miller DD, et al. I-387, a novel antimitotic indole, displays a potent in vitro and in vivo antitumor activity with less neurotoxicity. Mol Cancer Ther. 2010;9(11):2859-68.